Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori,Caterina Gregorio,Marie Robin,Nico Gagelmann,Carmelo Gurnari,Somedeb Ball,Juan Carlos Caballero Berrocal,Luca Lanino,Saverio D'Amico,Marta Spreafico,Giulia Maggioni,Erica Travaglino,Elisabetta Sauta,Manja Meggendorfer,Lin-Pierre Zhao,Alessia Campagna,Victor Savevski,Armando Santoro,Najla Al Ali,David Sallman,Francesc Sole,Guillermo Garcia-Manero,Ulrich Germing,Nicolaus Kroger,Shahram Kordasti,Valeria Santini,Guillermo Sanz,Wolfgang Kern,Uwe Platzbecker,Maria Diez-Campelo,Jaroslaw P. Maciejewski,Lionel Ades,Pierre Fenaux,Torsten Haferlach,Amer M. Zeidan,Gastone Castellani,Rami Komrokji,Francesca Ieva,Matteo Giovanni Della Porta,Massimo Bernardi,Carmen Di Grazia,Luca Vago,Giulia Rivoli,Lorenza Borin,Patrizia Chiusolo,Luisa Giaccone,Maria Teresa Voso,Jan Philipp Bewersdorf,Olivier Nibourel,Marina Díaz Beyá,Andrés Jerez,Francisca Hernández,Kyra Velázquez Kennedy,Blanca Xicoy,Marta Ubezio,Antonio Russo,Gabriele Todisco,Daniele Mannina,Stefania Bramanti,Matteo Zampini,Elena Riva,Marilena Bicchieri,Gianluca Asti,Filippo Viviani,Alessandro Buizza,Benedetta Tinterri,Anne-Sophie Kubasch,Andrea Bacigalupo,Anna Maria Raiola,Alessandro Rambaldi,Francesco Passamonti,Fabio Ciceri,GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET
DOI: https://doi.org/10.1200/jco.23.02175
IF: 45.3
2024-05-10
Journal of Clinical Oncology
Abstract:PURPOSE Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation being a crucial question. Here, we aimed to develop and validate a decision support system to define the optimal timing of HSCT for patients with MDS on the basis of clinical and genomic information as provided by the Molecular International Prognostic Scoring System (IPSS-M). PATIENTS AND METHODS We studied a retrospective population of 7,118 patients, stratified into training and validation cohorts. A decision strategy was built to estimate the average survival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clinical and genomic covariates and to determine the optimal transplantation policy by comparing different strategies. RESULTS Under an IPSS-M based policy, patients with either low and moderate-low risk benefited from a delayed transplantation policy, whereas in those belonging to moderately high-, high- and very high-risk categories, immediate transplantation was associated with a prolonged life expectancy (RMST). Modeling decision analysis on IPSS-M versus conventional Revised IPSS (IPSS-R) changed the transplantation policy in a significant proportion of patients (15% of patient candidate to be immediately transplanted under an IPSS-R–based policy would benefit from a delayed strategy by IPSS-M, whereas 19% of candidates to delayed transplantation by IPSS-R would benefit from immediate HSCT by IPSS-M), resulting in a significant gain-in-life expectancy under an IPSS-M–based policy ( P = .001). CONCLUSION These results provide evidence for the clinical relevance of including genomic features into the transplantation decision making process, allowing personalizing the hazards and effectiveness of HSCT in patients with MDS.
oncology